Polynucleotide Eye Treatment in Doncaster

The under-eye area presents a unique combination of challenges that makes it one of the most complex zones to treat effectively in aesthetics. The skin of the lower eyelid is the thinnest on the face — approximately 0.5mm — and beneath it lies a fragile fat compartment, orbital septum tissue and a network of small blood vessels whose visibility through the translucent skin contributes to the blue-purple discolouration most people experience as dark circles. As we age, the skin thins further, the fat compartment can diminish and reposition, and the structural support that keeps the under-eye area smooth and even progressively declines.

Conventional approaches to the under-eye area — tear trough filler, skin boosters, topical treatments — each address different aspects of this complex picture. Polynucleotides offer a fundamentally different approach: rather than filling, hydrating or lifting the existing tissue, they trigger the tissue to regenerate itself. PDRN — polydeoxyribonucleotide, the active component of polynucleotide injections — stimulates fibroblast proliferation, promotes new collagen and elastin synthesis, and supports the growth of new blood vessels and cellular matrix within the treated tissue. The result, over a course of four sessions, is a genuine improvement in the quality, thickness and structural integrity of the periorbital tissue — producing visible improvements in dark circles, under-eye hollowing and crepey skin that reflect real tissue change.

Furthermore, polynucleotide eye treatment works well as a standalone periorbital treatment or in combination with tear trough filler, LaseMD eye treatment or SuneKOS eye treatment, addressing different dimensions of the under-eye concern from complementary angles. Your practitioner will discuss the most appropriate single or combined approach at consultation.

Our Doncaster clinic is on Thorne Road with on-site parking, and we welcome patients from across South Yorkshire including Rotherham, Wakefield, Sheffield, Leeds and Barnsley.

What Are Polynucleotides and How Do They Work in the Eye Area?

Polynucleotides — also referred to as PDRN (polydeoxyribonucleotide) or PN — are chains of nucleotides derived from highly purified salmon DNA. Their biological activity is based on their ability to bind to adenosine A2A receptors on the surface of fibroblasts — the cells responsible for producing collagen, elastin and the extracellular matrix that gives skin its structural quality.

When polynucleotides are injected into the periorbital tissue, they activate these receptors and trigger a cascade of regenerative responses:

Fibroblast proliferation: Polynucleotides stimulate fibroblasts to divide and multiply, increasing the density of the collagen-producing cell population in the treated tissue. Consequently, the tissue’s ongoing capacity to produce structural proteins is directly enhanced.

New collagen and elastin synthesis: The activated fibroblasts produce new collagen and elastin, thickening and re-densifying the dermal matrix in the periorbital zone. This structural improvement directly addresses the thinning and fragility that makes the under-eye area look hollow and crepey.

Angiogenesis support: PDRN supports the formation of new blood vessels in the treated tissue, improving local circulation and cellular nutrition. This is particularly significant for dark circles with a vascular component — improved circulation in the under-eye area can reduce the pooling of deoxygenated blood that contributes to the blue-purple discolouration.

Anti-inflammatory activity: Polynucleotides have documented anti-inflammatory properties, reducing the chronic low-level inflammation in the periorbital tissue that accelerates structural degradation and contributes to puffiness and dullness.

The combined effect of these responses — delivered over a course of four sessions at four-week intervals — is a progressive and genuine improvement in periorbital tissue quality that accumulates as each treatment builds on the regenerative response of the previous one.

The clinical evidence for PDRN and polynucleotide therapy in tissue regeneration, collagen synthesis and periorbital skin quality is supported by peer-reviewed research. British Journal of Dermatology — polynucleotides and skin regeneration

How Is Polynucleotide Eye Treatment Performed? Step by Step

Before treatment:

• A full consultation is held to assess the periorbital area, the nature of your under-eye concerns and your suitability for treatment
• Avoid blood-thinning supplements, alcohol and non-essential NSAIDs for 24 hours before treatment to minimise bruising risk
• Topical anaesthetic cream is applied to the periorbital area approximately 20–30 minutes before the injections to maximise comfort

During treatment:

• The periorbital skin is thoroughly cleansed
• PDRN is injected into precisely targeted points across the periorbital zone — typically using a fine needle technique for the under-eye area
• Small papule blebs (raised bumps at injection sites) appear immediately after injection — this is normal and expected and indicates the product has been placed correctly in the superficial tissue
• The procedure takes approximately 30 minutes including preparation

After treatment:

• The papule blebs typically resolve within 24 to 96 hours as the polynucleotides disperse through the tissue
• Swelling and bruising may occur and are normal; these typically resolve within 48 to 72 hours
• Avoid touching, pressing or applying makeup to the under-eye area for 24 hours following treatment
• Apply broad-spectrum SPF whenever outdoors throughout the course
• Visible results are expected from approximately 30 days after the first session as the regenerative process develops
• Maximum results are seen following completion of a course of four sessions

The Purpose of Polynucleotide Eye Treatment

Restoring Periorbital Tissue Quality Through True PDRN-Driven Regeneration

The primary purpose of polynucleotide eye treatment is to restore the structural quality of the periorbital tissue — not by adding volume or hydration to what is already there, but by triggering the tissue to produce new collagen, elastin and extracellular matrix components from within. This regenerative mechanism is fundamentally different from filler (which adds volume), skin boosters (which add hydration) and laser resurfacing (which stimulates surface remodelling). Polynucleotides address the cellular foundation of periorbital tissue quality, producing improvements in dark circles, hollowing and crepey texture that reflect genuine structural tissue change.

Maintaining Improved Periorbital Tissue Quality Through a Regular Treatment Course and Maintenance Programme

The regenerative response triggered by polynucleotide eye treatment builds progressively across a course of four sessions — each treatment deepening the fibroblast activation and collagen synthesis response established by the previous one. Maintenance treatments following the initial course sustain the elevated tissue quality achieved, supporting the periorbital area against the ongoing structural decline that ageing continues to produce. Your practitioner will discuss the appropriate maintenance interval at your final course session.

Protecting Confidence and Wellbeing by Addressing the Under-Eye Area’s Most Persistent Visible Concerns

Dark circles and under-eye hollowing are among the most consistently self-consciousness-inducing facial concerns — they create the appearance of tiredness and ageing that patients feel is disproportionate to how they actually feel, and they are resistant to concealment, skincare and general health improvements alike. Providing a non-surgical injectable treatment that addresses these concerns through genuine tissue regeneration — producing improvements that are real, progressive and structural — offers meaningful relief from a concern that significantly affects how patients see themselves and how confident they feel in their appearance.

7 Proven Benefits of Polynucleotide Eye Treatment

1. Addresses dark circles through vascular and structural improvement Polynucleotides’ support for angiogenesis and tissue regeneration addresses both the vascular and structural components of dark circles — improving periorbital circulation and thickening the skin that allows blood vessels to show through.

2. Improves under-eye hollowing through dermal matrix regeneration New collagen and elastin synthesis triggered by PDRN re-densifies the periorbital dermal matrix, progressively improving the hollow, sunken appearance beneath the eyes over a course of sessions.

3. Reduces crepey periorbital texture through tissue thickening The thinning and fragile quality of crepey periorbital skin responds to polynucleotides’ fibroblast-stimulating activity, with progressive improvement in skin thickness, firmness and texture as the regenerative process matures.

4. Anti-inflammatory properties reduce puffiness and dullness PDRN’s documented anti-inflammatory activity reduces the chronic low-level inflammation in the periorbital tissue that contributes to puffiness and a dull, fatigued appearance in the eye area.

5. Produces genuine tissue regeneration rather than temporary volume addition Unlike filler or skin boosters, polynucleotides do not add to existing tissue — they trigger the tissue to regenerate itself, producing structural improvements that reflect real cellular change.

6. Safe and well-tolerated in the delicate periorbital zone Polynucleotide formulations are biocompatible, highly purified and well-tolerated in the thin, sensitive periorbital tissue. They do not carry the same risks of migration or volume distortion that filler in the tear trough area can produce.

7. Combines with complementary eye area treatments for comprehensive results Polynucleotide eye treatment combines effectively with LaseMD eye treatment for surface resurfacing, SuneKOS eye treatment for amino acid-based regeneration and tear trough filler for volume correction where structural hollowing is the primary concern.

What Can Polynucleotide Eye Treatment Address?

Dark Circles

Dark circles have multiple contributing causes — the most common being thin periorbital skin that allows the blue-purple colour of underlying blood vessels to show through (vascular dark circles), and shadowing created by hollowing beneath the eyes (structural dark circles). Polynucleotides address both: the tissue-thickening effect of new collagen synthesis reduces the translucency that allows vascular show-through, and the angiogenic support improves periorbital circulation. Consequently, patients with both types of dark circles typically see improvement, though those with predominantly vascular dark circles tend to see the most striking change.

Under-Eye Hollowing

Mild to moderate hollowing beneath the eyes — where the orbital fat pad has diminished or redistributed and the under-eye area appears sunken or shadowed — responds well to polynucleotide eye treatment’s dermal matrix regeneration. As the fibroblast-stimulated new collagen and elastin accumulate in the treated tissue, the structural support beneath the lower eyelid is progressively restored, reducing the hollow, tired appearance. For more significant hollowing where structural volume correction is needed quickly, tear trough filler may be more appropriate or may be combined with polynucleotides for a more comprehensive result.

Crepey Periorbital Skin and Fine Lines

The thin, fragile, tissue-paper quality of crepey periorbital skin — and the fine lines that accumulate in this delicate zone — respond to polynucleotides’ tissue-thickening and collagen-stimulating activity. Progressive improvement in skin thickness, texture and firmness develops across a course of sessions as the regenerative response matures. The improvement in skin quality is complemented by laser resurfacing options (LaseMD eye or CO2 eye) for patients seeking both deep tissue regeneration and surface resurfacing together.

Overall Periorbital Skin Quality and Radiance

Beyond its specific targeted benefits, polynucleotide eye treatment produces a general improvement in the overall quality, hydration and radiance of the periorbital skin — the tissue simply looks healthier, more supported and more vital as the regenerative process develops.

Polynucleotide Eye vs Tear Trough Filler — Which Is Right for Me?

Tear trough filler uses hyaluronic acid dermal filler to add volume directly to the tear trough — the groove between the lower eyelid and the upper cheek — to reduce the shadow and hollowing that creates the tired under-eye appearance. Results are immediate and can be reversed with hyaluronidase. It is the most appropriate choice when structural volume loss is the primary and predominant concern and when an immediate visible improvement is wanted.

Polynucleotide eye treatment works through regeneration rather than volume addition — it is the appropriate choice when the primary concern is skin quality, dark circles, crepey texture and tissue health rather than structural volume loss, or when the patient wants a regenerative approach that improves the tissue itself rather than adding a foreign substance.

In practice, the two approaches are frequently complementary: polynucleotides to improve the tissue quality and address vascular dark circles, and tear trough filler to correct structural hollowing where present. Many patients benefit from both as part of a comprehensive under-eye improvement programme. Your practitioner will assess which is most appropriate for your specific presentation at consultation.

Polynucleotide Eye vs SuneKOS Eye — Understanding the Difference

SuneKOS eye treatment uses a formulation of hyaluronic acid combined with a proprietary blend of amino acids to stimulate collagen and elastin production in the periorbital tissue, improving skin quality, hydration and structural support around the eyes.

Both polynucleotides and SuneKOS stimulate collagen production in the periorbital tissue — but through different mechanisms. SuneKOS provides the building blocks (amino acids and HA) that the skin needs to synthesise new collagen. Polynucleotides work at the receptor level, directly activating the fibroblasts that produce collagen and additionally supporting angiogenesis and anti-inflammatory activity.

The choice between them depends on the specific concern profile and the depth of regeneration required. Your practitioner will assess the most appropriate option, or combination, at consultation.

Why Choose Elements Medical for Polynucleotide Eye Treatment in Doncaster?

The periorbital area is one of the most technically demanding injection zones in facial aesthetics — its thin skin, delicate underlying structures and proximity to the eye all require precise technique and a thorough understanding of periorbital anatomy. At Elements Medical, polynucleotide eye treatment is performed by experienced practitioners with specific training in periorbital injection technique, and every treatment begins with a thorough consultation and facial assessment.

We offer polynucleotide eye treatment as part of a comprehensive eye area treatment range that also includes LaseMD eye, CO2 eye, SuneKOS eye and tear trough filler. We will always recommend the treatment or combination that is genuinely best matched to your periorbital concerns and goals.

Read what our patients say on our Google Reviews page